Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 295
- Registration Number
- NCT02750514
- Locations
- 🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Californa, Los Angeles (UCLA), Los Angeles, California, United States
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-03-22
- Target Recruit Count
- 60
- Registration Number
- NCT02744768
- Locations
- 🇮🇹
Az.Ospedaliera S.G.Moscati, Avellino, Italy
🇮🇹Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano, Milano, Italy
🇮🇹Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2650
- Registration Number
- NCT02733445
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT02720185
- Locations
- 🇺🇸
University of Illinois Hospital and Health Systems (Outpatient Care Center), Chicago, Illinois, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Emory University
- Target Recruit Count
- 7
- Registration Number
- NCT02709083
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02690922
- Locations
- 🇨🇳
Tongji hospital, Wuhan, Hubei, China
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT02689440
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Emory University
- Registration Number
- NCT02680951
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- University of Regensburg
- Target Recruit Count
- 4
- Registration Number
- NCT02596828
- Locations
- 🇩🇪
University Hospital of Regensburg, Regensburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.